Appointment is effective on September 1, 2015
Gordon Dunn will continue as Vice President, Finance Director, Europe
ATHLONE, Ireland, July 1, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL) today announced that Jose (Pepe) Carmona, previously the Chief Financial Officer of a division of Alcon, a Novartis company, has been appointed Chief Financial Officer effective September 1, 2015. Gordon Dunn, Innocoll’s current Chief Financial Officer, will continue with the company as Vice President, Finance Director, Europe. The executive changes were made to add further commercialization experience to the senior management team as the company prepares to transition to a fully-integrated specialty pharmaceutical company.
“As Innocoll continues to execute on the transition of the organization, it is essential that our leadership team has the skills and experience required to successfully lead a commercial-stage company,” said Tony Zook, Chief Executive Officer of Innocoll. “Jose’s extensive background with major pharmaceutical and personal care companies is the skill set that will help propel the company to its next stage in its development. We very much thank Gordon for his contributions as CFO and appreciate his continued commitment to the company by heading our European financial operations.”
Mr. Carmona has over 19 years of experience applying his extensive management skills toward the financial operations of commercial-stage companies. Most recently he served as Chief Financial Officer of Alcon Europe, Middle East & Africa, a division of Novartis, and prior to that he held numerous financial management positions with increasing responsibility within Novartis. Before joining Novartis in 2003, Mr. Carmona held senior management positions for several divisions of Proctor and Gamble in Latin America. Mr. Carmona received his B.S. in Industrial and Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.
“I am very pleased to be joining Innocoll at such an exciting stage in its development,” said Mr. Carmona. “The company could face a rapid transition from a clinical development-stage company to a company with multiple self-marketed products in the very near term. It will be a momentous time at Innocoll and I look forward to contributing to the company’s continued success.”
Mr. Dunn added, “I am extremely proud of what we accomplished at Innocoll during my tenure as the company’s CFO. We raised the capital necessary to build a strong drug formulation platform and set the stage for commercialization. I look forward to working with Pepe who will apply his commercial-stage experience toward moving the company to the next level at exactly the right time in the company’s development.”
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The company’s late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The company’s approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and EUSA Pharma. All of the company’s products and product candidates are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany. CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.
“Any statements in this press release about our future expectations, plans and prospects, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including statements about the clinical trials of Cogenzia. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in developing and commercializing our products and product candidates, the timing for results, the initiation, conduct and timing of clinical trials, delays in potential approvals by FDA of the commencement of trials, availability of data from clinical trials, positive results from such trials and timing and expectations for regulatory approvals, our scientific approach and general development progress, the composition of our supervisory board, the availability or commercial potential of our product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section of our Annual Report on Form 20-F for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.”